<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923269</url>
  </required_header>
  <id_info>
    <org_study_id>17834</org_study_id>
    <secondary_id>J2V-MC-GZLA</secondary_id>
    <nct_id>NCT04923269</nct_id>
  </id_info>
  <brief_title>A Study of LY3532226 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3532226 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of the study drug&#xD;
      known as LY3532226 in healthy participants. Blood tests will be performed to check how much&#xD;
      LY3532226 gets into the bloodstream and how long it takes the body to eliminate it. This&#xD;
      study will last approximately 8 weeks including screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">November 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3532226</measure>
    <time_frame>Day 1 through Day 43</time_frame>
    <description>PK: Cmax of LY3532226</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3532226</measure>
    <time_frame>Day 1 through Day 43</time_frame>
    <description>PK: AUC of LY3532226</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Concentration (Tmax) of LY3532226</measure>
    <time_frame>Day 1 through Day 43</time_frame>
    <description>PK: Tmax of LY3532226</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3532226</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of LY3532226 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3532226</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3532226</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy males or females not of childbearing potential.&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 18.5 to 40 kilograms per meter squared&#xD;
             (kg/m²), inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a significant history of or current CV (e.g., myocardial infarction, congestive&#xD;
             heart failure, cerebrovascular accident, venous thromboembolism), respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders&#xD;
             capable of significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             of constituting a risk while taking the study intervention; or of interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Have a history of malignancy within 5 years prior to screening&#xD;
&#xD;
          -  Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis&#xD;
&#xD;
          -  Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2X the&#xD;
             upper limit of normal (ULN) or total bilirubin level (TBL) &gt;1.5X ULN&#xD;
&#xD;
          -  Have serum triglyceride level ≥5 mmol/L (442.5 mg/dL)&#xD;
&#xD;
          -  Have undergone any form of bariatric surgery&#xD;
&#xD;
          -  Have received systemic or inhaled glucocorticoid therapy (excluding topical,&#xD;
             intraarticular, and intraocular preparations); for more than 14 consecutive days&#xD;
             within 4 weeks before screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 1, 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

